New prognostic model in patients with advanced urothelial carcinoma treated with second-line immune checkpoint inhibitors

Autor: Ernest Choy, Yohann Loriot, Fabio Calabrò, Cora N Sternberg, Guillermo De Velasco, Daniel Castellano, Roubini Zakopoulou, Aristotelis Bamias, Nicholas James, Axel Merseburger, F Lopez-Rios, Mario Kramer, Kimon Tzannis

Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 11, Iss 1 (2023)

Background Bellmunt Risk Score, based on Eastern Cooperative Oncology Group (ECOG) performance status (PS), hemoglobin levels and presence of liver metastases, is the most established prognostic algorithm for patients with advanced urothelial cancer

Externí odkaz: https://doaj.org/article/a82e3f41ebdc4c3989d1f4211495a2b2

Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022

Autor: Silke Gillessen, Alberto Bossi, Ian D. Davis, Johann de Bono, Karim Fizazi, Nicholas D. James, Nicolas Mottet, Neal Shore, Eric Small, Matthew Smith, Christopher Sweeney, Bertrand Tombal, Emmanuel S. Antonarakis, Ana M. Aparicio, Andrew J. Armstrong, Gerhardt Attard, Tomasz M. Beer, Himisha Beltran, Anders Bjartell, Pierre Blanchard, Alberto Briganti, Rob G. Bristow, Muhammad Bulbul, Orazio Caffo, Daniel Castellano, Elena Castro, Heather H. Cheng, Kim N. Chi, Simon Chowdhury, Caroline S. Clarke, Noel Clarke, Gedske Daugaard, Maria De Santis, Ignacio Duran, Ros Eeles, Eleni Efstathiou, Jason Efstathiou, Onyeanunam Ngozi Ekeke, Christopher P. Evans, Stefano Fanti, Felix Y. Feng, Valerie Fonteyne, Nicola Fossati, Mark Frydenberg, Daniel George, Martin Gleave, Gwenaelle Gravis, Susan Halabi, Daniel Heinrich, Ken Herrmann, Celestia Higano, Michael S. Hofman, Lisa G. Horvath, Maha Hussain, Barbara Alicja Jereczek-Fossa, Robert Jones, Ravindran Kanesvaran, Pirkko-Liisa Kellokumpu-Lehtinen, Raja B. Khauli, Laurence Klotz, Gero Kramer, Raya Leibowitz, Christopher J. Logothetis, Brandon A. Mahal, Fernando Maluf, Joaquin Mateo, David Matheson, Niven Mehra, Axel Merseburger, Alicia K. Morgans, Michael J. Morris, Hind Mrabti, Deborah Mukherji, Declan G. Murphy, Vedang Murthy, Paul L. Nguyen, William K. Oh, Piet Ost, Joe M. O'Sullivan, Anwar R. Padhani, Carmel Pezaro, Darren M.C. Poon, Colin C. Pritchard, Danny M. Rabah, Dana Rathkopf, Robert E. Reiter, Mark. A. Rubin, Charles J. Ryan, Fred Saad, Juan Pablo Sade, Oliver A. Sartor, Howard I. Scher, Nima Sharifi, Iwona Skoneczna, Howard Soule, Daniel E. Spratt, Sandy Srinivas, Cora N. Sternberg, Thomas Steuber, Hiroyoshi Suzuki, Matthew R. Sydes, Mary-Ellen Taplin, Derya Tilki, Levent Türkeri, Fabio Turco, Hiroji Uemura, Hirotsugu Uemura, Yüksel Ürün, Claire L. Vale, Inge van Oort, Neha Vapiwala, Jochen Walz, Kosj Yamoah, Dingwei Ye, Evan Y. Yu, Almudena Zapatero, Thomas Zilli, Aurelius Omlin

Publikováno v: European Urology, 83, 267-293
Gillessen, S, Bossi, A, Davis, I D, de Bono, J, Fizazi, K, James, N D, Mottet, N, Shore, N, Small, E, Smith, M, Sweeney, C, Tombal, B, Antonarakis, E S, Aparicio, A M, Armstrong, A J, Attard, G, Beer, T M, Beltran, H, Bjartell, A, Blanchard, P, Briganti, A, Bristow, R G, Bulbul, M, Caffo, O, Castellano, D, Castro, E, Cheng, H H, Chi, K N, Chowdhury, S, Clarke, C S, Clarke, N, Daugaard, G, De Santis, M, Duran, I, Eeles, R, Efstathiou, E, Efstathiou, J, Ngozi Ekeke, O, Evans, C P, Fanti, S, Feng, F Y, Fonteyne, V, Fossati, N, Frydenberg, M, George, D, Gleave, M, Gravis, G, Halabi, S, Heinrich, D, Herrmann, K, Higano, C, Hofman, M S, Horvath, L G, Hussain, M, Jereczek-Fossa, B A, Jones, R, Kanesvaran, R, Kellokumpu-Lehtinen, P L, Khauli, R B, Klotz, L, Kramer, G, Leibowitz, R, Logothetis, C J, Mahal, B A, Maluf, F, Mateo, J, Matheson, D, Mehra, N, Merseburger, A, Morgans, A K, Morris, M J, Mrabti, H, Mukherji, D, Murphy, D G, Murthy, V, Nguyen, P L, Oh, W K, Ost, P, O'Sullivan, J M, Padhani, A R, Pezaro, C, Poon, D M C, Pritchard, C C, Rabah, D M, Rathkopf, D, Reiter, R E, Rubin, M A, Ryan, C J, Saad, F, Pablo Sade, J, Sartor, O A, Scher, H I, Sharifi, N, Skoneczna, I, Soule, H, Spratt, D E, Srinivas, S, Sternberg, C N, Steuber, T, Suzuki, H, Sydes, M R, Taplin, M E, Tilki, D, Türkeri, L, Turco, F, Uemura, H, Uemura, H, Ürün, Y, Vale, C L, van Oort, I, Vapiwala, N, Walz, J, Yamoah, K, Ye, D, Yu, E Y, Zapatero, A, Zilli, T & Omlin, A 2023, ' Management of Patients with Advanced Prostate Cancer. Part I : Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022 ', European Urology, vol. 83, no. 3, pp. 267-293 . https://doi.org/10.1016/j.eururo.2022.11.002
European Urology, 83, 3, pp. 267-293
Scientia
Gillessen, S, Bossi, A, Davis, I D, de Bono, J, Fizazi, K, James, N D, Mottet, N, Shore, N, Small, E, Smith, M, Sweeney, C, Tombal, B, Antonarakis, E S, Aparicio, A M, Armstrong, A J, Attard, G, Beer, T M, Beltran, H, Bjartell, A, Blanchard, P, Briganti, A, Bristow, R G, Bulbul, M, Caffo, O, Castellano, D, Castro, E, Cheng, H H, Chi, K N, Chowdhury, S, Clarke, C S, Clarke, N, Daugaard, G, De Santis, M, Duran, I, Eeles, R, Efstathiou, E, Efstathiou, J, Ngozi Ekeke, O, Evans, C P, Fanti, S, Feng, F Y, Fonteyne, V, Fossati, N, Frydenberg, M, George, D, Gleave, M, Gravis, G, Halabi, S, Heinrich, D, Herrmann, K, Higano, C, Hofman, M S, Horvath, L G, Hussain, M, Alicja Jereczek-Fossa, B, Jones, R, Kanesvaran, R, Kellokumpu-Lehtinen, P L, Khauli, R B, Klotz, L, Kramer, G, Leibowitz, R, Logothetis, C J, Mahal, B A, Maluf, F, Mateo, J, Matheson, D, Mehra, N, Merseburger, A, Morgans, A K, Morris, M J, Mrabti, H, Mukherji, D, Murphy, D G, Murthy, V, Nguyen, P L, Oh, W K, Ost, P, O'Sullivan, J M, Padhani, A R, Pezaro, C, Poon, D M C, Pritchard, C C, Rabah, D M, Rathkopf, D, Reiter, R E, Rubin, M A, Ryan, C J, Saad, F, Pablo Sade, J, Sartor, O A, Scher, H I, Sharifi, N, Skoneczna, I, Soule, H, Spratt, D E, Srinivas, S, Sternberg, C N, Steuber, T, Suzuki, H, Sydes, M R, Taplin, M E, Tilki, D, Türkeri, L, Turco, F, Uemura, H, Uemura, H, Ürün, Y, Vale, C L, van Oort, I, Vapiwala, N, Walz, J, Yamoah, K, Ye, D, Yu, E Y, Zapatero, A, Zilli, T & Omlin, A 2023, ' Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022 ', European Urology, vol. 83, no. 3, pp. 267-293 . https://doi.org/10.1016/j.eururo.2022.11.002

Contains fulltext : 291600.pdf (Publisher’s version ) (Open Access) BACKGROUND: Innovations in imaging and molecular characterisation and the evolution of new therapies have improved outcomes in advanced prostate cancer. Nonetheless, we continue to

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::babb241ad2da71dd1b20e3e0850e61fa
http://hdl.handle.net/2066/291600

A novel immunotherapy prognostic score for patients with pretreated advanced urInary TrAct CArcinoma from the subgroup analysis of the SAUL study: the ITACA Score

Autor: Giuseppe FORNARINI, Sara E. REBUZZI, Sebastiano BUTI, Pasquale RESCIGNO, Axel MERSEBURGER, Cora N. STERNBERG, Ugo de GIORGI, Umberto BASSO, Marco MARUZZO, Patrizia GIANNATEMPO, Marta PONZANO, Emilio F. GIUNTA, Fabio CATALANO, Veronica MURIANNI, Alessandra DAMASSI, Malvina CREMANTE, Annalice GANDINI, Silvia PUGLISI, Miguel A. LLAJA OBISPO, Alessio SIGNORI, Giuseppe L. BANNA

Publikováno v: Minerva urology and nephrology.

The current prognostic models for patients with advanced urinary tract cancers were developed and validated in the chemotherapy setting. As immunotherapy has become the backbone of novel treatments, updated prognostic scores are needed.A comprehensiv

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::97e1ac692bc1a6c3514ab129720c2d08
https://pubmed.ncbi.nlm.nih.gov/36511379

A novel immunotherapy prognostic score for patients with pretreated advanced urinary tract carcinoma from the subgroup analysis of the SAUL study. The urInary TrAct CArcinoma score (ITACA)

Autor: Giuseppe Fornarini, Sara Elena Rebuzzi, Sebastiano Buti, Pasquale Rescigno, Axel Merseburger, Ugo de Giorgi, Umberto Basso, Marco Maruzzo, Patrizia Giannatempo, Marta Ponzano, Emilio Francesco Giunta, Fabio Catalano, Veronica Murianni, Alessandra Damassi, Malvina Cremante, Annalice Gandini, Silvia Puglisi, Miguel Angel Llaja Obispo, Alessio Signori, Giuseppe Luigi Banna

Background The current prognostic models for patients with advanced urinary tract cancers were developed and validated in the chemotherapy setting. As immunotherapy has become the backbone of novel treatments, updated prognostic scores are needed. Me

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::916322df52e90c4bc4b74e5fa4899ded
https://doi.org/10.1101/2022.08.30.22279352

Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Autor: Thomas Powles, Piotr Tomczak, Se Hoon Park, Balaji Venugopal, Thomas Ferguson, Stefan N Symeonides, Jaroslav Hajek, Howard Gurney, Yen-Hwa Chang, Jae Lyun Lee, Naveed Sarwar, Antoine Thiery-Vuillemin, Marine Gross-Goupil, Mauricio Mahave, Naomi B Haas, Piotr Sawrycki, Joseph E Burgents, Lei Xu, Kentaro Imai, David I Quinn, Toni K Choueiri, Toni Choueiri, Thomas R. Ferguson, Tzu-Ping Lin, Stefan N. Symeonides, Naomi B. Haas, Howard P. Gurney, Christine Chevreau, John M. Burke, Gurjyot Doshi, Bohuslav Melichar, Delphine Topart, Stephane Oudard, Evgeniy Kopyltsov, Hans-Joerg Hammers, David I. Quinn, Ajjai Alva, Juliana de Janoski Menezes, Adriano Goncalves e Silva, Eric W. Winquist, Alketa Hamzaj, Giuseppe Procopio, Boguslawa Karaszewska, Ewa M. Nowakowska-Zajdel, Boris Y. Alekseev, Rustem A. Gafanov, Adel Izmailov, Andrey Semenov, Sergey G. Afanasyev, Oleg N. Lipatov, Thomas B. Powles, Sandy Srinivas, David McDermott, Samith T. Kochuparambil, Ian D. Davis, Katriina Peltola, Roberto Sabbatini, Jinsoo Chung, Michail I. Shkolnik, Vsevolod B. Matveev, Pablo Gajate Borau, Steven McCune, Thomas E. Hutson, Alejandro Dri, Silvio Correia Sales, Carrie Yeung, Carmen Marcela Alcala Castro, Peter Bostrom, Brigitte Laguerre, Consuelo Buttigliero, Ugo de Giorgi, Eugeniy A. Fomin, Yousef Zakharia, Clara Hwang, Eric A. Singer, Jeffrey T. Yorio, David Waterhouse, Ruben Dario Kowalyszyn, Margarita Sonia Alfie, Eduardo Yanez Ruiz, Tomas Buchler, Krista Kankaanranta, Gianluigi Ferretti, Go Kimura, Kazuo Nishimura, Naoya Masumori, Satoshi Tamada, Haruaki Kato, Hiroshi Kitamura, Iwona Danielewicz, Joanna Wojcik-Tomaszewska, Nuria Sala Gonzalez, Kun-Yuan Chiu, Michael B. Atkins, Elisabeth Heath, Gustavo Adolfo Rojas-Uribe, Manuel Enrique Gonzalez Fernandez, Susan Feyerabend, Sandro Pignata, Kazuyuki Numakura, Bozena Cybulska Stopa, Ruslan Zukov, Miguel Angel Climent Duran, Pablo Jose Maroto Rey, Alvaro Montesa Pino, Chao-Hsiang Chang, Salil Vengalil, Tom S. Waddell, Patrick W. Cobb, Ralph Hauke, Daniel M. Anderson, John Sarantopoulos, Theodore Gourdin, Tian Zhang, Gautam Jayram, Luis Enrique Fein, Carole Harris, Patricia Medeiros Milhomem Beato, Francisco Flores, Angela Estay, Juan Andres Rubiano, Jens Bedke, Stefan Hauser, Andreas Neisius, Jonas Busch, Satoshi Anai, Hiroyuki Tsunemori, Dariusz Sawka, Bozena Sikora-Kupis, Jose Angel Arranz, Ignacio Delgado, Chung-Hsin Chen, Elizabeth Gunderson, Scott Tykodi, Alan Koletsky, Kevin Chen, Manish Agrawal, Diego Lucas Kaen, Juan Pablo Sade, Marcelo Daniel Tatangelo, Francis Parnis, Fernando Maciel Barbosa, Genevieve Faucher, Nayyer Iqbal, Daniele Marceau, Jean-Benoit Paradis, Nawar Hanna, Alejandro Acevedo, Carolina Ibanez, Luis Villanueva, Pedro Pablo Galaz, Isabel Cristina Durango, Ray Manneh, Zdenek - Kral, Petra Holeckova, Heikki Hakkarainen, Hanna Ronkainen, Sophie Abadie-Lacourtoisie, Sophie Tartas, Peter J. Goebell, Marc-Oliver Grimm, Thomas Hoefner, Manfred Wirth, Andrej Panic, Wolfgang Schultze-Seemann, Akira Yokomizo, Ryuichi Mizuno, Hirotsugu Uemura, Masatoshi Eto, Masao Tsujihata, Yoshihisa Matsukawa, Yoji Murakami, Miso Kim, Paul Hamberg, Malgorzata Marczewska-Skrodzka, Cezary Szczylik, Alison C. Humphreys, Peter Jiang, Birendra Kumar, Gary Lu, Arpita Desai, Jose Antonio Karam, George Keogh, Mark Fleming, Juan Jose Zarba, Viviana E. Leiva, Guillermo Ariel Mendez, Samuel J. Harris, Stephen J. Brown, Joao Neif Antonio Junior, Rita de Cassia Costamilan, Roberto Odebrecht Rocha, David Muniz, Leandro Brust, Aly-Khan Lalani, Jeffrey Graham, Michael Levesque, Francisco Orlandi, Rostislav Kotasek, Jean L. Deville, Delphine Borchiellini, Axel Merseburger, Michael Rink, Frederik Roos, Ray McDermott, Masafumi Oyama, Yoshiaki Yamamoto, Yoshihiko Tomita, Yuji Miura, Naomasa Ioritani, Hans Westgeest, Tomasz Kubiatowski, Wieslaw Bal, Regina Girones Sarrio, Julie Rowe, Debra M. Prow, Francis Senecal, Neda Hashemi-Sadraei, Scott W. Cole, Stephan D. Kendall, Donald A. Richards, Ian D. Schnadig, Mukul Gupta

Publikováno v: 2022, ' Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial ', The Lancet Oncology, vol. 23, no. 9, pp. 1133-1144 . https://doi.org/10.1016/S1470-2045(22)00487-9

Background: The first interim analysis of the KEYNOTE-564 study showed improved disease-free survival with adjuvant pembrolizumab compared with placebo after surgery in patients with clear cell renal cell carcinoma at an increased risk of recurrence.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::25f8e8bb143ec0a3a46038772a01c57f
https://pubmed.ncbi.nlm.nih.gov/36603923